Oligosaccharide composition for treating acute respiratory tract infections

Patent metadata

Field	Value
Publication number	US-9763465-B2
Application number	US-201113988975-A
Country	US
Kind code	B2
Filing date	Nov 21, 2011
Priority date	Nov 23, 2010
Publication date	Sep 19, 2017
Grant date	Sep 19, 2017

Abstract

The inventions discloses a composition comprising at least one N-acetyl lactosamine, at least one sialylated oligosaccharide and at least one fucosylated oligosaccharide, for use in preventing acute respiratory infections (ARI) and/or relieving symptoms of said ARI infections. Preferably said composition is a starter infant formula. Said acute respiratory infection is in particular bronchiolitis or otitis.

First claim

The invention claimed is:

1. A method for relieving symptoms of otitis media or bronchiolitis, the method comprising administering a nutritional composition comprising oligosaccharides comprising equal parts of (i) at least one N-acetyl lactosamine comprising lacto-N-neotetraose, (ii) at least one sialylated oligosaccharide comprising 6′ sialyllactose, and (iii) at least one fucosylated oligosaccharide comprising 2′ fucosyllactose to an infant or young child who suffers from a condition selected from the group consisting of otitis media and bronchiolitis, and at least one of the sialylated oligosaccharide or the fucosylated oligosaccharide is obtained by a process comprising a step selected from the group consisting of isolation from a natural source by filtration, isolation from a natural source by chromatographic technology, chemical synthesis, and biotechnological synthesis.

2. The method according to claim 1 , wherein the at least one N-acetyl-lactosamine further comprises lacto-N-tetraose.

3. The method according to claim 1 , wherein the at least one sialylated oligosaccharide further comprises 3′ sialyllactose.

4. The method according to claim 1 , wherein the at least one fucosylated oligosaccharide comprises an additional fucosylated oligosaccharide selected from the group consisting of 3-fucosyllactose, difucosyllactose, lacto-N-fucopentaoses, lacto-N-difucohexaose I, fucosyllacto-N-hexaose, Difucosyllacto-N-hexaose I and Difucosyllacto-N-neohexaose II.

5. The method according to claim 1 , wherein the nutritional composition comprises at least one probiotic bacterial strain.

6. The method according to claim 1 , wherein the nutritional composition comprises at least one prebiotic.

7. The method according to claim 1 , wherein the synthetic nutritional composition comprises at least one phage or a mixture of phages.

8. The method according to claim 1 , wherein the nutritional composition is a starter infant formula, an infant formula, a follow-on formula, a baby food formula, an infant cereals formula or a growing-up milk.

9. The method according to claim 1 , wherein the infant or young child suffers from otitis media.

10. The method according to claim 1 , comprising the step of administering the nutritional composition before and/or during a weaning period.

11. The method according to claim 1 , wherein the infant or young child is an infant, and the nutritional composition is administered to ease the breathing process, decrease pain, ease sleep, and/or relieve symptoms in the infant.

12. A method for the treatment of otitis media or bronchiolitis, the method comprising:
administering to an infant or young child who suffers from a condition selected from the group consisting of otitis media and bronchiolitis a nutritional composition comprising equal parts of (i) at least one N-acetyl lactosamine comprising lacto-N-neotetraose, (ii) at least one sialylated oligosaccharide comprising 6′ sialyllactose, and (iii) at least one fucosylated oligosaccharide comprising 2′ fucosyllactose, and at least one of the sialylated oligosaccharide or the fucosylated oligosaccharide is obtained by a process comprising a step selected from the group consisting of isolation from a natural source by filtration, isolation from a natural source by chromatographic technology, chemical synthesis, and biotechnological synthesis.

13. The method according to claim 1 , wherein the nutritional composition is a supplement.

14. The method of claim 1 , wherein the nutritional composition comprises hydrolyzed and/or partially hydrolyzed proteins.

15. The method according to claim 1 , wherein the nutritional composition is a starter infant formula.

16. The method according to claim 1 , wherein the oligosaccharides consist of the lacto-N-neoteraose, the 2′ fucosyllactose, and the 6′ sialyllactose.

17. The method according to claim 1 , wherein the lacto-N-neotetraose is synthesized chemically.

18. The method according to claim 1 , wherein isolation from the natural source comprises isolation from an animal milk.

19. The method according to claim 1 , wherein a daily dose of the at least one N-acetyl lactosamine is from 0.1 to 3 g.

20. The method according to claim 1 , wherein a daily dose of the at least one sialylated oligosaccharide is from 0.1 to 2 g.

21. The method according to claim 1 , wherein a daily dose of the at least one fucosylated oligosaccharide is from 0.1 to 3 g.

22. The method according to claim 1 , wherein the natural source is animal milk.

Assignees

• Sprenger Norbert
• Nestec Sa

Inventors

• Sprenger Norbert

Classifications

• A61P27/16

  Otologicals · CPC title

• A61P31/04

  Antibacterial agents · CPC title

• A61P31/00

  Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title

• A61P11/00

  Drugs for disorders of the respiratory system · CPC title

• A61K31/702

  Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages · CPC title